Abstract
Lung cancer is one of the malignant tumors with greatest morbidity and mortality around the world. The keys to targeted therapy are discovery of lung cancer biomarkers to facilitate improvement of survival and quality of life for the patients with lung cancer. Translationally controlled tumor protein (TCTP) is one of the most overexpressed proteins in human lung cancer cells by comparison to the normal cells, suggesting that it might be a good biomarker for lung cancer. In the present study, the targeted efficacy of dihydroartemisinin (DHA) on TCTP expression in the A549 lung cancer cell model was explored. DHA could inhibit A549 lung cancer cell proliferation, and simultaneously up-regulate the expression of TCTP mRNA, but down-regulate its protein expression in A549 cells. In addition, it promoted TCTP protein secretion. Therefore, TCTP might be used as a potential biomarker and therapeutic target for non-small cell lung cancers.
Highlights
Lung cancer, one of the malignant tumors, has high morbidity and mortality around the world, and its 5-year survival rate is only 8%-15% (Molina et al, 2006; AlHashimi et al, 2014; Cui et al, 2014)
Up-regulation of A549 cell Translationally controlled tumor protein (TCTP) mRNA The expression of A549 cell TCTP mRNA was explored under the action of 25 μmol/L and 100 μmol/L
Our studies indicated that DHA inhibited the growth of A549 lung cancer cells
Summary
One of the malignant tumors, has high morbidity and mortality around the world, and its 5-year survival rate is only 8%-15% (Molina et al, 2006; AlHashimi et al, 2014; Cui et al, 2014). Nonsmall cell lung cancer (NSCLC) accounts for 80% of all pulmonary carcinomas. Targeted therapies are commonly used in combination with traditional chemotherapy currently (Liloglou et al, 2014), and targeted drugs are more effective and have less severe side effects than standard chemotherapy drugs (Lammers et al, 2012). Under these circumstances, discovery of novel and effective biomarkers for lung cancer diagnosis and prognosis as well as new therapeutic targets becomes imperative
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
